Overview

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

Up to 18 women with ovarian cancer will administer up to two injections of SPL-108 daily in combination with weekly doses of Paclitaxel. They will be monitored for safety and efficacy for up to 6 months, until disease progression or unacceptable toxicity.

Phase:

Phase 1

Details

Lead Sponsor:

Splash Pharmaceuticals, Inc.

Treatments:

Paclitaxel